Developer docs
API playgroundTry for free, no card

Search company profiles

Euformatics

Full company profile

uuid0004anq

Namestring
Euformatics
Websiteurl
euformatics.com
Company typeenum
Private
Founded yearint
2010
Descriptiontext

Euformatics is a Finland-based, privately held bioinformatics company founded in 2010 and headquartered in Espoo. The firm builds software tools that interpret genomic sequence data, with product positioning aimed at delivering cancer-relevant variant interpretation from a single test — implying a consolidated clinical reporting workflow aimed at clinical genetics and oncology reference workflows rather than a broad life-science research audience. The company operates as a small for-profit with 1-10 employees, consistent with a focused specialist vendor serving clinical laboratories, hospital genetics departments, or research consortia in Nordic and European markets.

The company's underlying technology stack centers on bioinformatics interpretation pipelines — variant calling, annotation, and clinical interpretation logic — though no detailed architectural disclosures (core engine, supported assays, validation status, or certifications such as IVDR/CE-IVD) are present in the available data. No app, SDK, MCP, or API documentation is recorded, suggesting the product is most likely delivered as a service, on-prem pipeline, or licensed analysis platform rather than a self-serve cloud product. Revenue mechanics are not disclosed; the absence of pricing details, customer logos, or named channels indicates a low-volume, high-touch commercial motion typical of a niche clinical bioinformatics vendor.

Euformatics' only documented external capital event is a ~$365K European Commission grant in July 2022, structured as non-dilutive public funding led by the Commission itself. No venture rounds, M&A, partnerships, executive appointments, product launches, or regulatory milestones are recorded in the source data. The combination of small headcount, single grant funding event, and absent commercial disclosures signals a firm that is either in early commercialization, sustained by public/grant funding, or operating in a low-volume services-plus-software hybrid mode.

Short descriptiontext

Euformatics is a Finland-based bioinformatics company that builds software tools to interpret genomic sequence data, with a focus on delivering cancer-relevant variant interpretation from a single test for clinical and research users.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEspoo, Finland
HQ citystring
Espoo
HQ countrystring
Finland
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
clinical bioinformatics software, cancer genomics interpretation, sequence data analysis, variant interpretation tools, oncology diagnostics software
Industry3 codes
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine
NAICS code1 code
  • Software Publishers5132
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Clinical Bioinformatics Software
Social media profiles1 record
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Euformatics develops and supplies high-standard bioinformatics software tools used to interpret next-generation sequencing (NGS) data. Its offering emphasizes a single-test capability that surfaces all cancer-relevant clinical genomic findings, supporting clinical laboratories and diagnostic providers in standardized oncology sequence interpretation.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Euformatics Cancer Bioinformatics Interpretation Tool
CategoryClinical Bioinformatics Software
Description

Standardized bioinformatics software used by clinical laboratories and molecular diagnostic providers to interpret next-generation sequencing data and produce all cancer-relevant clinical genomic findings from a single test.

Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

BC Platforms is a Finland-headquartered genomics data and analytics company providing interpretation software for clinical and research workflows, making it a near-twin peer for Euformatics in both geography and offering.

TypeDirect peer
Description

Sophia Genetics offers the SOPHiA DDM platform for clinical genomic and multi-omic data interpretation, directly overlapping with Euformatics' cancer-focused sequence interpretation tools and similar hospital lab buyers.

TypeDirect peer
Description

Molecular Health offers clinical decision support and genomic interpretation for oncology and rare disease, targeting the same hospital and reference lab buyers as Euformatics.

TypeDirect peer
Description

GenomOncology provides clinical genomics decision support specifically for molecular tumor boards and oncology interpretation, directly comparable to Euformatics' cancer-focused workflow.

TypeDirect peer
Description

Congenica delivers a clinical genomics interpretation platform (Congenica Insights) for rare disease and cancer, competing directly with Euformatics for molecular pathology and clinical lab customers.

TypeBroad incumbent
Description

QIAGEN's Digital Insights business (including QCI Interpret) offers clinical NGS interpretation as part of a broader sample-to-insight portfolio, competing with Euformatics for clinical interpretation workflows from a position of much greater scale and breadth.

TypeDirect peer
Description

Velsera provides the Clinical Genomics Workspace for NGS interpretation and clinical reporting, serving hospital and reference labs with comparable cancer interpretation workflows to Euformatics.

TypeDirect peer
Description

Fabric Genomics delivers AI-driven clinical NGS interpretation software for hereditary disease and oncology, directly comparable in product scope and customer base to Euformatics' interpretation tools.

9BlueBee (Illumina)
TypeEmerging player
Description

BlueBee, now part of Illumina, provides clinical genomics data processing and interpretation infrastructure for sequencing-based diagnostics, overlapping with Euformatics on interpretation software delivery models.

TypeBroad incumbent
Description

Roche's Navify digital health portfolio includes clinical decision support and oncology workflow tools that intersect with Euformatics' interpretation offerings as part of a broader diagnostics and pathology portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Euformatics

Clinical Bioinformatics Softwareeuformatics.com

Euformatics is a Finland-based bioinformatics company that builds software tools to interpret genomic sequence data, with a focus on delivering cancer-relevant variant interpretation from a single test for clinical and research users.

What Euformatics does

Euformatics is a Finland-based, privately held bioinformatics company founded in 2010 and headquartered in Espoo. The firm builds software tools that interpret genomic sequence data, with product positioning aimed at delivering cancer-relevant variant interpretation from a single test — implying a consolidated clinical reporting workflow aimed at clinical genetics and oncology reference workflows rather than a broad life-science research audience. The company operates as a small for-profit with 1-10 employees, consistent with a focused specialist vendor serving clinical laboratories, hospital genetics departments, or research consortia in Nordic and European markets.

The company's underlying technology stack centers on bioinformatics interpretation pipelines — variant calling, annotation, and clinical interpretation logic — though no detailed architectural disclosures (core engine, supported assays, validation status, or certifications such as IVDR/CE-IVD) are present in the available data. No app, SDK, MCP, or API documentation is recorded, suggesting the product is most likely delivered as a service, on-prem pipeline, or licensed analysis platform rather than a self-serve cloud product. Revenue mechanics are not disclosed; the absence of pricing details, customer logos, or named channels indicates a low-volume, high-touch commercial motion typical of a niche clinical bioinformatics vendor.

Euformatics' only documented external capital event is a ~$365K European Commission grant in July 2022, structured as non-dilutive public funding led by the Commission itself. No venture rounds, M&A, partnerships, executive appointments, product launches, or regulatory milestones are recorded in the source data. The combination of small headcount, single grant funding event, and absent commercial disclosures signals a firm that is either in early commercialization, sustained by public/grant funding, or operating in a low-volume services-plus-software hybrid mode.

Euformatics firmographics

Firmographics
Name
Euformatics
Website
https://euformatics.com
Company type
Private
Founded year
2010
Operating status
Operating
Headcount range
11–50 employees
Short description
Euformatics is a Finland-based bioinformatics company that builds software tools to interpret genomic sequence data, with a focus on delivering cancer-relevant variant interpretation from a single test for clinical and research users.
Ownership category
akta.pro rank

Euformatics industry classification

Industry
Product category
Clinical Bioinformatics Software
NAICS
Software Publishers (5132)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAJAD
Bioinformatics & Multi-omics Analysis Software
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAAANAA
Genomic Profiling & Sequencing-Based Precision Medicine

Keywords

  • Clinical bioinformatics software
  • Cancer genomics interpretation
  • Sequence data analysis
  • Variant interpretation tools
  • Oncology diagnostics software

Where Euformatics is headquartered

Location

Headquarters

HQ city
Espoo
HQ country
Finland
HQ region
Europe

Markets served

Euformatics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Euformatics product offering

Product offering

Core offering

Euformatics develops and supplies high-standard bioinformatics software tools used to interpret next-generation sequencing (NGS) data. Its offering emphasizes a single-test capability that surfaces all cancer-relevant clinical genomic findings, supporting clinical laboratories and diagnostic providers in standardized oncology sequence interpretation.

Differentiator

Problem solved

Functional benefit

Products and services

  • Euformatics Cancer Bioinformatics Interpretation Tool Standardized bioinformatics software used by clinical laboratories and molecular diagnostic providers to interpret next-generation sequencing data and produce all cancer-relevant clinical genomic findings from a single test.

Companies that use Euformatics

Customer profile

Ideal customer profiles1 record

Euformatics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Euformatics partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights2 records

Euformatics competitors and assessment

Company assessment

Direct peers

  • BC Platforms: BC Platforms is a Finland-headquartered genomics data and analytics company providing interpretation software for clinical and research workflows, making it a near-twin peer for Euformatics in both geography and offering.
  • Sophia Genetics: Sophia Genetics offers the SOPHiA DDM platform for clinical genomic and multi-omic data interpretation, directly overlapping with Euformatics' cancer-focused sequence interpretation tools and similar hospital lab buyers.
  • Molecular Health: Molecular Health offers clinical decision support and genomic interpretation for oncology and rare disease, targeting the same hospital and reference lab buyers as Euformatics.
  • GenomOncology: GenomOncology provides clinical genomics decision support specifically for molecular tumor boards and oncology interpretation, directly comparable to Euformatics' cancer-focused workflow.
  • Congenica: Congenica delivers a clinical genomics interpretation platform (Congenica Insights) for rare disease and cancer, competing directly with Euformatics for molecular pathology and clinical lab customers.
  • Velsera (formerly PierianDx): Velsera provides the Clinical Genomics Workspace for NGS interpretation and clinical reporting, serving hospital and reference labs with comparable cancer interpretation workflows to Euformatics.
  • Fabric Genomics (renamed Genomic Answers): Fabric Genomics delivers AI-driven clinical NGS interpretation software for hereditary disease and oncology, directly comparable in product scope and customer base to Euformatics' interpretation tools.

Broad incumbents

  • QIAGEN Digital Insights: QIAGEN's Digital Insights business (including QCI Interpret) offers clinical NGS interpretation as part of a broader sample-to-insight portfolio, competing with Euformatics for clinical interpretation workflows from a position of much greater scale and breadth.
  • Roche (Navify): Roche's Navify digital health portfolio includes clinical decision support and oncology workflow tools that intersect with Euformatics' interpretation offerings as part of a broader diagnostics and pathology portfolio.

Emerging players

  • BlueBee (Illumina): BlueBee, now part of Illumina, provides clinical genomics data processing and interpretation infrastructure for sequencing-based diagnostics, overlapping with Euformatics on interpretation software delivery models.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

Euformatics social profiles

Digital presence

Euformatics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Euformatics leadership team

Management profile

Number of profiles

Euformatics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Euformatics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Euformatics

What does Euformatics do?

Euformatics develops and supplies high-standard bioinformatics software tools used to interpret next-generation sequencing (NGS) data. Its offering emphasizes a single-test capability that surfaces all cancer-relevant clinical genomic findings, supporting clinical laboratories and diagnostic providers in standardized oncology sequence interpretation.

When was Euformatics founded?

Euformatics was founded in 2010. It employs 11 to 50 people.

Where is Euformatics based?

Euformatics is headquartered in Espoo, Finland, in the Europe region.

Who are Euformatics's main competitors?

Direct peers on record are BC Platforms, Sophia Genetics, Molecular Health, GenomOncology, Congenica, Velsera (formerly PierianDx) and Fabric Genomics (renamed Genomic Answers). Broad incumbents are QIAGEN Digital Insights and Roche (Navify). BlueBee (Illumina) is listed as an emerging player.

Does Euformatics have an API?

No public API is recorded for Euformatics.

What industry is Euformatics in?

Euformatics's product category is Clinical Bioinformatics Software. Its primary akta.pro industry code is HLAGAJAD, Bioinformatics & Multi-omics Analysis Software, with a secondary code of HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services. Its NAICS code is 5132 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals